塔乌尔苏氧胆酸 (TUDCA) 降低ER压力,减少性结肠炎的疾病活动
Vladimir Lamm1, Katherine Huang1, Ruishu Deng2
1Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.
陶鲁苏氧胆酸 (TUDCA) 改善了患者的性结肠炎 (UC) 症状,并减少了患者的内分泌网膜 (ER) 压力. 这项开放性试验表明,TUDCA是活跃UC的有希望的治疗方法.
科学领域:
- 胃肠病学 胃肠病学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 细胞内膜网膜 (ER) 应激和蛋白质错折有助于在炎症性肠病中表皮屏障功能障碍.
- 胆汁酸Tauroursodeoxycholic acid (TUDCA) 是一种胆汁酸,在临床前模型中充当化学伴侣,减轻ER压力和减少大肠炎.
研究的目的:
- 评估口服TUDCA在患有活性性结肠炎 (UC) 的患者的安全性和有效性.
- 评估TUDCA对ER压力标志物,粘膜愈合和UC患者临床疾病活性的影响.
主要方法:
- 这是一项开放性试验,涉及中度至重度活性UC患者,接受口服TUDCA (1.75或2g/天) 6周.
- 主要结果:ER压力标志物的变化. 二级结局:安全性,耐受性和临床,内镜和组织学疾病活动的变化.
主要成果:
- 图德卡耐受性很好,过渡性消化不良是最常见的副作用.
- 在粘膜活检中观察到ER压力和炎症的显著减少.
- 到第6周,UC疾病活动的临床,内镜和组织学测量有明显的改善.
结论:
- 6周的口服TUDCA治疗在活跃的性结肠炎患者中是安全有效的.
- TUDCA促进粘膜愈合,减轻ER压力,并减少临床疾病活动.
- 建议进行随机对照试验,进一步调查TUDCA作为UC的辅助疗法.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
